Hide

FocusBar

Subscribe to Premium Member
Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M52,171Revenue $M16,427Net Margin (%)20.9Z-Score4.1
Enterprise Value $M60,212EPS $3.4Operating Margin %25.6F-Score5
P/E(ttm))15.2Cash Flow Per Share $4.4Pre-tax Margin (%)25.6Higher ROA y-yY
Price/Book3.010-y EBITDA Growth Rate %6.0Quick Ratio1.3Cash flow > EarningsY
Price/Sales3.25-y EBITDA Growth Rate %13.1Current Ratio1.4Lower Leverage y-yN
Price/Cash Flow9.7y-y EBITDA Growth Rate %-2.5ROA % (ttm)10.0Higher Current Ratio y-yY
Dividend Yield %2.0Insider Buy (3m)0ROE % (ttm)18.6Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M1,014ROI % (ttm)15.0Gross Margin Increase y-yN

Gurus Latest Trades with MDT

Please Subscribe to see portfolio changes after the end of the last quarter. Real Time Picks are included for Premium Members only! Plans start from as little as $299/year.

7-Day FREE TRIAL
Number of guru portfolios checked: 51.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
MDTJames Barrow 2013-03-31 Add0.12%$41.02 - $47.22
($45.42)
$ 51.3313%Add 4.9%30,813,326
MDTJohn Hussman 2013-03-31 Reduce-1.25%$41.02 - $47.22
($45.42)
$ 51.3313%Reduce -69.54%503,300
MDTYacktman Focused Fund 2013-03-31 Sold Out -0.26%$41.02 - $47.22
($45.42)
$ 51.3313%Sold Out0
MDTYacktman Fund 2013-03-31 Sold Out -0.23%$41.02 - $47.22
($45.42)
$ 51.3313%Sold Out0
MDTDonald Yacktman 2013-03-31 Sold Out -0.1%$41.02 - $47.22
($45.42)
$ 51.3313%Sold Out0
MDTRay Dalio 2013-03-31 Reduce-0.02%$41.02 - $47.22
($45.42)
$ 51.3313%Reduce -25.25%165,445
MDTYacktman Focused Fund 2012-12-31 Buy 0.26%$40.75 - $44.67
($42.32)
$ 51.3321%New holding, 400000 sh.400,000
MDTJoel Greenblatt 2012-12-31 Add0.23%$40.75 - $44.67
($42.32)
$ 51.3321%Add 186.95%152,490
MDTRay Dalio 2012-12-31 Buy 0.09%$40.75 - $44.67
($42.32)
$ 51.3321%New holding, 221345 sh.221,345
MDTJohn Hussman 2012-09-30 Add0.26%$37.35 - $43.47
($40.12)
$ 51.3328%Add 16.65%1,751,200
MDTRay Dalio 2012-09-30 Sold Out -0.06%$37.35 - $43.47
($40.12)
$ 51.3328%Sold Out0
MDTGeorge Soros 2012-06-30 Sold Out -0.06%$35.89 - $39.39
($37.69)
$ 51.3336%Sold Out0
MDTJohn Hussman 2012-03-31 Add0.18%$37.51 - $40.65
($36.71)
$ 51.3340%Add 20.1%1,501,200
MDTJoel Greenblatt 2012-03-31 Add0.07%$37.51 - $40.65
($36.71)
$ 51.3340%Add 53.12%62,035
MDTGeorge Soros 2012-03-31 Buy 0.06%$37.51 - $40.65
($36.71)
$ 51.3340%New holding, 100000 sh.100,000
MDTRay Dalio 2012-03-31 Add0.02%$37.51 - $40.65
($36.71)
$ 51.3340%Add 40.51%122,100
MDTJohn Keeley 2012-03-31 Add0.01%$37.51 - $40.65
($36.71)
$ 51.3340%Add 52.62%49,190
MDTJames Barrow 2011-12-31 Add0.34%$31.79 - $38.34
($34.67)
$ 51.3348%Add 15.9%29,987,882
MDTJohn Paulson 2011-12-31 Sold Out -0.32%$31.79 - $38.34
($34.67)
$ 51.3348%Sold Out0
MDTRay Dalio 2011-12-31 Reduce-0.11%$31.79 - $38.34
($34.67)
$ 51.3348%Reduce -70.68%86,900
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

MDT is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
MDT James Barrow 2013-03-3130,813,3263.042.6+4.9%
MDT Scott Black 2013-03-3120,89400.13+1.33%
MDT Vanguard Health Care Fund 2013-03-3110,801,1001.072
MDT Jean-Marie Eveillard 2013-03-318,00000
MDT John Keeley 2013-03-3149,07000.05-0.61%
MDT Arnold Van Den Berg 2013-03-31303,5030.031.4-1.7%
MDT Dodge & Cox 2013-03-319,936,3930.980.57-4.14%
MDT PRIMECAP Management 2013-03-3132,434,3213.22.2-11.66%
MDT Joel Greenblatt 2013-03-31129,8420.010.31-14.85%
MDT Ray Dalio 2013-03-31165,4450.020.07-25.25%
MDT John Hussman 2013-03-31503,3000.050.87-69.54%
MDT Donald Yacktman 2013-03-31000Sold Out
MDT Yacktman Fund 2013-03-31000Sold Out
MDT Yacktman Focused Fund 2013-03-31000Sold Out
MDT Scott Black 2012-12-3120,61900.12-1.25%
Premium Most recent portfolio changes are included for Premium Members only!


MDT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
ANDERSON RICHARD HDirector 2013-05-22Buy4,800$52.32-1.64view
ANDERSON RICHARD HDirector 2012-06-18Buy5,200$37.9435.64view
BUTEL JEAN LUCEVP & Group Pres MDT Intl 2012-01-11Sell58,740$38.8132.59view
Powell Kendall JDirector 2011-09-01Buy3,000$35.246.19view
SCHULER JACK WDirector 2011-09-01Buy10,000$35.1446.44view
ANDERSON RICHARD HDirector 2011-08-31Buy3,000$35.2346.07view
OConnell Christopher JEVP & GroupPres Restora Therap 2011-08-04Sell4,000$33.9851.44view
SCHULER JACK WDirector 2011-05-25Buy25,000$40.726.44view
SCHULER JACK WDirector 2010-12-22Buy100,000$37.0638.86view
Lenehan James TDirector 2010-07-06Buy3,000$36.2741.88view

Press Releases about MDT:

Quarterly/Annual Reports about MDT:

News about MDT:

Articles On GuruFocus.com
Diamond Hill Capital Update and Top Three May 14 2013 
Attractively valued dividend stocks to consider today May 14 2013 
My 4 Favorite Dividend Aristocrats with Highest Profitability May 07 2013 
20 Dividend Champions with Highest 10-Year Dividend Growth Rates Apr 24 2013 
Busy Selling - Yacktman Focused Fund First Quarter Apr 12 2013 
Yacktman Fund - Texas Billionaire Guru Adds and Sells First Quarter Apr 12 2013 
How Much Money Will You Need Before Retiring? Mar 06 2013 
Early Movers for Tuesday Feb. 19, 2013 Feb 19 2013 
My 3 Favorites of the 20 Most-Recommended Dividend Champions Dec 31 2012 
Why Cooperman and Price Are Betting on Boston Scientific’s Turnaround Dec 31 2012 

More From Our Partners
Medtronic Receives CE Mark for CoreValve System May 23 2013 - BENZINGA

Add Notes, Comments or Ask Questions

Comments

No comment yet
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial
FEEDBACK